These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6468509)

  • 1. The kinetics of interferon clearance in mice: comparison of mouse and human interferon.
    Kiuchi Y; Yonehara M; Okada K; Suzuki J; Kobayashi S
    Jikken Dobutsu; 1984 Jan; 33(1):85-9. PubMed ID: 6468509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of disappearance from blood and lymphatic delivery of human fibroblast interferon in rat by different administration routes.
    Yoshikawa H; Satoh Y; Naruse N; Takada K; Muranishi S
    J Pharmacobiodyn; 1985 Mar; 8(3):206-10. PubMed ID: 4009412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of human interferons].
    Furue H; Kobayashi H; Komuro T; Kako M; Mugitani H; Fuse K; Kaise R; Nagai K; Takahashi T; Hirota F
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):935-42. PubMed ID: 6721508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of rates of clearance of human fibroblast and leukocyte interferon from the circulatory system of rabbits.
    Edy VG; Billiau A; De Somer P
    J Infect Dis; 1976 Jun; 133 Suppl():A18-21. PubMed ID: 932502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of human recombinant interferon-beta in monkeys and rabbits.
    Gomi K; Morimoto M; Inoue A; Kobayashi H; Deguchi T; Hara T; Nakamizo N
    Gan; 1984 Mar; 75(3):292-300. PubMed ID: 6724230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection.
    Wills RJ; Dennis S; Spiegel HE; Gibson DM; Nadler PI
    Clin Pharmacol Ther; 1984 May; 35(5):722-7. PubMed ID: 6713784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the in vivo priming effect of interferon in mice.
    Rosztóczy I
    J Gen Virol; 1986 Dec; 67 ( Pt 12)():2731-7. PubMed ID: 3794665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: comparison of intravenous, intramuscular, and intraventricular delivery.
    Collins JM; Riccardi R; Trown P; O'Neill D; Poplack DG
    Cancer Drug Deliv; 1985; 2(4):247-53. PubMed ID: 4063949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of human leukocyte interferon.
    Cantell K; Pyhälä L
    J Infect Dis; 1976 Jun; 133 Suppl():A6-12. PubMed ID: 932506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tissue distribution of recombinant human alpha A, D, A/D(Bgl), and I interferons and mouse alpha-interferon in mice.
    Bohoslawec O; Trown PW; Wills RJ
    J Interferon Res; 1986 Jun; 6(3):207-13. PubMed ID: 3745986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interferons--its method of administration and adverse effect related to pharmacokinetics ].
    Furue H
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):186-93. PubMed ID: 6582804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different pharmacokinetics between natural and recombinant human interferon beta in rabbits.
    Satoh YI; Kasama K; Kajita A; Shimizu H; Ida N
    J Interferon Res; 1984; 4(3):411-22. PubMed ID: 6491398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical application of fibroblast interferon--an overview.
    Billiau A
    Med Oncol Tumor Pharmacother; 1984; 1(2):87-96. PubMed ID: 6400034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of human leukocyte interferon pharmacology with a monoclonal antibody.
    Rosenblum MG; Unger BW; Gutterman JU; Hersh EM; David GS; Frincke JM
    Cancer Res; 1985 Jun; 45(6):2421-4. PubMed ID: 3986783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of human fibroblast interferon on the growth of human melanoma cells implanted in nude mice.
    Ida N; Uenishi N; Kajita A; Satoh Y
    Gan; 1982 Dec; 73(6):952-60. PubMed ID: 7160584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous and intramuscular pharmacokinetics of recombinant leukocyte A interferon.
    Bornemann LD; Spiegel HE; Dziewanowska ZE; Krown SE; Colburn WA
    Eur J Clin Pharmacol; 1985; 28(4):469-71. PubMed ID: 4029251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intranasally applied medication during a cold.
    Phillpotts RJ; Davies HW; Willman J; Tyrrell DA; Higgins PG
    Antiviral Res; 1984 Apr; 4(1-2):71-4. PubMed ID: 6742821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice.
    McKenna SD; Vergilis K; Arulanandam AR; Weiser WY; Nabioullin R; Tepper MA
    J Interferon Cytokine Res; 2004 Feb; 24(2):119-29. PubMed ID: 14980076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effects of murine recombinant interferon-beta administered by intravenous, intramuscular or subcutaneous route on mouse hepatitis virus infection.
    Matsuyama S; Henmi S; Ichihara N; Sone S; Kikuchi T; Ariga T; Taguchi F
    Antiviral Res; 2000 Aug; 47(2):131-7. PubMed ID: 10996401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers.
    Kirkwood JM; Ernstoff MS; Davis CA; Reiss M; Ferraresi R; Rudnick SA
    Ann Intern Med; 1985 Jul; 103(1):32-6. PubMed ID: 4003987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.